Inovio Biomedical said regulators in South Korea granted its affiliate, VGX International, approval to begin a first-stage trial of an experimental DNA vaccine against H5N1 flu. Inovio said it plans to start testing the vaccine in the U.S. later this year as it works on a DNA-based universal flu vaccine.

Related Summaries